News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Prima Biomed (PRR.AX) Release: Further CAN-003 Trial Information Will be Presented by Dr. Jeffrey Goh at the European Cancer Congress in Amsterdam on October 1st, 2013

9/24/2013 10:47:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

September 24, 2013 -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) is advises that CEO Matthew Lehman has conducted an interview with Boardroom Radio on the Company’s recently released top-line data from its CAN-003 (Phase 2) study of CVac™ for the treatment of epithelial ovarian cancer patients in first or second remission.

The interview is available via the following link;

Further CAN-003 trial information will be presented by Dr. Jeffrey Goh at the European Cancer Congress in Amsterdam on October 1st, 2013.

About the CAN-003 trial

CAN-003 is a 63-patient phase 2 study evaluating the effects of CVac, as compared to an observation-only control arm, in epithelial ovarian cancer patients in complete remission after first or second line treatment. The primary objectives of the trial are to determine the safety of CVac administration and to determine CVac’s effect on progression-free survival. Secondary objectives of the trial are to determine CVac’s effect of overall survival and to evaluate host immunologic responses to CVac. In accordance with the protocol design, the first seven patients on the trial were all assigned to receive CVac in order to test the comparability of product manufacturing in a new facility. The subsequent 56 patients were randomized in a 1:1 fashion and assigned to either the CVac group or observational control group.

About Prima BioMed

Prima BioMed is a globally active leader in the development of personalized bio-therapeutic products for cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission and soon starting in trials for pancreatic, colorectal, and triple-negative breast cancers.

For further information please contact:

For further information please contact:

USA Investor/Media:

Ms. Jessica Brown

Prima BioMed Ltd.

+1 (919) 710-9061

Australia Investor/Media:

Mr. James Moses

Mandate Corporate

+61 (0) 420 991 574

Europe Investor/Media:

Mr. Axel Muhlhaus

edicto GmbH

+49 (0) 69 905505-52

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus